Techboard Startup Ranking #9
For the period ending 13 January 2016
After a short break during the Christmas period, Techboard’s startup and tech company ranking returns this week, with an exceptional four weeks’ worth of news and events to track since our last ranking!
Regenerative medicine group Orthocell has topped the first ranking of the year, following the announcement it had been granted a US patent for its ‘cell factory’ technology. As a result of the announcement its shares have soared 50% over the past fortnight, and the news was widely covered in the national press. Founded a decade ago, Orthocell is developing products and therapies to assist with repairing musculoskeletal injuries, based on a technology which was originally developed by UWA.
Here is a taster of the top 100 in Techboard’s latest startup ranking for the fortnight ending 13 January 2016
[table id=22 /]
Sign up/Log in to see the top 100
Amcom Upstart graduate Team Ahoy is the second most trending startup over the period, having launched the first public release of their project management software. The news was picked up by the startup press locally and nationally, and also resulted in two nominations from Techboard’s panel of experts.
Founder Damian Bramanis has greatly benefited from being based in Perth.
“I’ve found that Perth has been the perfect location to launch TeamAhoy: not only is there a thriving and supportive tech community, but people here really understand the challenges of remote and distributed teams.”
Listed digital media group migme completes the top 3. The Perth company which is now based in Singapore has been expanding its social entertainment reach into Southeast Asia and acquired two Indonesian firms, Hipwee and Shopdeca. Some see in migme a potential competitor to Facebook, in particular in the emerging Asian markets.
Other startups in our top 10 include two companies about to list, gaming startup Virtual Gaming Worlds which is in the process of completing a reverse take-over, and super-antibiotics play Recce with an over-subscribed IPO. Recce’s founder Dr Graham Melrose commented:
“We appreciate the public support of Recce and their recognition that we are making a real contribution in an enormous health challenge to the world. We have immediate challenges of international pre-clinical testing of RECCE antibiotics and the perfection of our very economic and versatile synthetic method of production.”
Check out the Archives: